Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)
Recruiting
The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms. Participants will: Undergo treatment with the Contour Neurovascular System Complete follow-up visits at 1month, 12months, and 24 months, following their procedure Report any adverse events to their study team
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/18/2025
Locations: University at Buffalo Neurosurgery, Buffalo, New York +3 locations
Conditions: Cerebral Aneurysms
The CONFORM Pivotal Trial
Recruiting
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Grandview Medical Center, Birmingham, Alabama +66 locations
Conditions: Atrial Fibrillation, Stroke
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2)
Recruiting
This is an open-label, multi-center, multi-cohort, non-randomized Phase 1 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with Immune-Mediated Diseases (IMD) including systemic sclerosis \[SSc\], idiopathic inflammatory myopathies \[IIM\], and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis \[AAV\].
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/18/2025
Locations: Nkarta Investigational Site, Orange, California +9 locations
Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
Recruiting
The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois +4 locations
Conditions: Heart Transplant, Heart Failure, Transplant; Failure, Heart
Geisinger Antibiotic Allergy Pilot Program: Assess and Address
Recruiting
This is a prospective non-inferiority study to evaluate penicillin allergy history in patients with reported penicillin allergy, who require penicillin or penicillin-derivative antibiotic during inpatient admission using a focused questionnaire. A simplified scoring system will be assigned to patient responses, and the total score will be utilized to identify low-risk patients that have a minimal risk of allergic reactions on exposure to penicillin or its derivative. Patients determined to have... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Geisinger Medical Center, Danville, Pennsylvania +2 locations
Conditions: Penicillin Allergy
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Recruiting
This study consists of two parts: phase 2 (Part A) and phase 3 (Part B). It is a multicenter study designed to evaluate the safety, effectiveness, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD, and to evaluate the safety and tolerabili... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/18/2025
Locations: University of California Irvine, Orange, California +15 locations
Conditions: Sickle Cell Disease Vaso-occlusive Crisis
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Recruiting
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/18/2025
Locations: Banner Sun Health Research Institute, Sun City, Arizona +43 locations
Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Strategy for Improving Stroke Treatment Response
Recruiting
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +48 locations
Conditions: Ischemic Stroke
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Recruiting
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: California Medical Research Associates Inc., Northridge, California +9 locations
Conditions: Severe Asthma
Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay
Recruiting
This is a national-level research study of neurologists and dementia specialists. The purpose of this study is to assess the clinical evaluation and management recommendations made by practicing providers for patient simulations with symptoms of cognitive decline.
Gender:
ALL
Ages:
All
Trial Updated:
08/18/2025
Locations: QURE Healthcare, Saint Louis, Missouri
Conditions: Alzheimer Disease (AD), Cognitive Decline
The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults
Recruiting
To critically examine biological, clinical, and behavioral modulators of progressive resistance training-associated exercise response heterogeneity in physical function and whole-body metabolism in older adults.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/18/2025
Locations: Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts +1 locations
Conditions: Aging, Mobility Disability
Developing and Pilot Testing an Intervention to Reduce Household Shisha Smoke Exposure Within Somali Homes
Recruiting
Previous qualitative research among Somali American adults in Minnesota have identified high levels of hookah or shisha (hereafter shisha) use in Somali households. Household shisha use exposes all family members, including children, to secondhand smoke (SHS) that contains toxins that can cause many different acute and chronic disease, including increased levels of several cancers such as lung, bladder, and oral cancers. Despite the high levels of shisha use, gaps in the knowledge of the risks o... Read More
Gender:
ALL
Ages:
6 months and above
Trial Updated:
08/18/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Shisha